Health economic review of recombinant activated factor VII for treatment of bleeding episodes in hemophilia patients with inhibitors

Expert Opinion on Pharmacotherapy

Volumn 8, Issue 8, 2007, Pages 1127-1136

  Stephens, Jennifer M ^a   Joshi, Ashish V ^b   Sumner, Michael ^b   Botteman, Marc F ^a  

^a PHARMERIT INTERNATIONAL   (United States)

^b NOVO NORDISK INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 DERIVATIVE; BLOOD CLOTTING FACTOR 8 INHIBITOR; BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING INHIBITOR; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ARTHROPATHY; BLEEDING; CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; ECONOMIC ASPECT; ELECTIVE SURGERY; EMBASE; HEALTH CARE COST; HEALTH ECONOMICS; HEMOPHILIA A; HEMOPHILIA B; HOSPITAL CHARGE; HOSPITALIZATION; HUMAN; IMMUNOLOGICAL TOLERANCE; MEDICAL DECISION MAKING; MEDLINE; META ANALYSIS; ORTHOPEDIC SURGERY; PHYSICAL DISABILITY; QUALITY OF LIFE; REVIEW; SYNOVITIS; SYSTEMATIC REVIEW;

BLOOD COAGULATION FACTOR INHIBITORS; COAGULANTS; DRUG COSTS; FACTOR VII; HEMOPHILIA A; HEMOPHILIA B; HEMORRHAGE; HUMANS; RECOMBINANT PROTEINS;

EID: 34250622844     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.8.8.1127     Document Type: Review

References (36)

1. KNIGHT C, PAISLEY S, WIGHT J, JONES ML: Economic modelling of different treatment strategies for haemophilia A with high-responding inhibitors. Haemophilia (2003) 9(4):521-540.
2. WIGHT J, PAISLEY S: The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia (2003) 9(4):418-435.
3. LUSHER JM: Recombinant Factor VIIa (NovoSeven) in the treatment of internal bleeding in patients with Factor VIII and IX inhibitors. Haemostasis (1996) 26(Suppl. 1):124-130.
4. LEISSINGER CA: Prevention of bleeds in hemophilia patients with inhibitors: emerging data and clinical direction. Am. J. Hematol. (2004) 77(2):187-193.
5. SCALONE L, MANTOVANI LG, MANNUCCI PM, GRINGERI A: Quality of life is associated to the orthopaedic status in haemophitic patients with inhibitors. Haemophilia (2006) 12(2):154-162.
6. CHANG H, SHER GD, BLANCHETTE VS, TEITEI JM: The impact of inhibitor on the cost of clotting factor replacement therapy in haemophilia A in Canada. Haemophilia (1999) 5(4):247-252.
7. GAUTIER P, D'ALCHE-GAUTIER MJ, COATMELEC B et al.: Cost related to replacement therapy during hospitalization of haemophiliacs with or without inhibitors: experience of six French haemophilia centres. Haemophilia (2002) 8(5):674-679.
8. COLOWICK AB, BOHN RL, AVORN J, EWENSTEIN BM: Immune tolerance induction in hemophilia patients with inhibitors: costly can be cheaper. Blood (2000) 96(5):1698-1702.
9. GREEN D: Complications associated with the treatment of haemophiliacs with inhibitors. Haemopbilia (1999) 5(Suppl. 3):11-17.
10. HEDNER U: Mechanism of action of recombinant Factor VII: an update. Semin. Hematol. (2006) 43(1 Suppl. 1):S105-S107
11. LLOYD JONES M, WIGHT J, PAISLEY S, KNIGHT C: Control of bleeding in patients with haemophilia A with inhibitors: a systematic review. Haemophilia (2003) 9(4):464-520.
12. KEY NS, ALEDORT LM, BEARDSLEY D et al.: Home treatment of mild to moderate bleeding episodes using recombinant Factor VIIa (Novoseven) in haemophiliacs with inhibitors. Thromb. Haemost. (1998) 80(6):912-918.
13. LAURIAN Y, GOUDEMAND J, NEGRIER C et al.: Use of recombinant activated Factor VII as first-line therapy for bleeding episodes in haemophiliacs with Factor VIII or IX inhibitors (NOSEPAC study). Blood Coagul. Fibrinolysis (1998) 9(Suppl. 1):S155.
14. LUSHER JM, ROBERTS HR, DAVIGNON G et al.: A randomized, double-blind comparison of two dosage levels of recombinant Factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. rFVIIa Study Group. Haemophilia (1998) 4(6):790-798.
15. PARAMESWARAN R, SHAPIRO AD, GILL JC, KESSLER CM: Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry. Haemophilia (2005) 11(2):100-106.
16. SANTAGOSTINO E, GRINGERI A, MANNUCCI PM: Home treatment with recombinant activated Factor VII in patients with Factor VIII inhibitors: the advantages of early intervention. Br. J. Haematol. (1999) 104(1):22-26.
17. ODEYEMI I, GUEST J: Modelling the economic impact of recombinant activated Factor VII compared to activated prothrombin-complex concentrate in the home treatment of a mild to moderate bleed in adults with inhibitors to clotting factors VIII and IX in the UK. J. Med. Econ. (2002) 5(1):119-133.
18. LUSHER JM: Acute hemarthroses: the benefits of early versus late treatment with recombinant activated Factor VII. Blood Coagul. Fibrinolysis (2000) 11(Suppl. 1):45-49.
19. MONAHAN PE, ALEDORT LM: Factors affecting choice of hemostatic agent for the hemophilia patient with an inhibitor antibody. Am. J. Hematol. (2004) 77(4):346-350.
20. GALANAUD JP, PELLETIER-FLEURY N, LOGEROT-LEBRUN H, LAMBERT T: Determinants of drug costs in hopitalised patients with haemophilia: impact of recombinant activated Factor VII. Pharmacoeconomics (2003) 21(10):699-707.
21. GRINGERI A, MANTOVANI LG, SCALONE L, MANNUCCI PM: Cost of care and QoL for patients with hemophilia complicated by inhibitors: the COCIS Study Group. Blood (2003) 102(7):2358-2363.
22. HARPER P, BRASSER M, MOORE L, TEAGUE L, PITCHER L, OCKELFORD P: The challenge arising from the cost of haemophilia care: an audit of haemophilia treatment at Auckland Hospital. N Z Med. J. (2003) 116(1180):U561.
23. GOUDEMAND J: Pharmaco-economic aspects of inhibitor treatment. Eur. J. Haematol. Suppl. (1998) 63:24-27.
24. EKERT H, BREWIN T, BOEY W, DAVEY P, TILDEN D: Cost-utility analysis of recombinant Factor VIIa (NovoSeven) in six children with long-standing inhibitors to Factor VIII or IX. Haemophilia (2001) 7(3):279-285.
25. ODEYEMI I, GUEST J: Modelling the economic impact of recombinant activated Factor VII and activated prothrombin-complex concentrate in the treatment ofa mild to moderate bleed in adults with inhibitors to clotting factors VIII and IX at a comprehensive care centre in the UK. J. Med. Econ (2002) 5(1):51-64.
26. DUNDAR S, ZULFIKAR B, KAVAKLI K et al.: A cost evaluation of treatment alternatives in mild-to-moderate bleeding episodes in haemophilia patients with inhibitors in Turkey. J. Med. Econ. (2005) 8(1):45-54.
27. PUTNAM KG, BOHN RL, EWENSTEIN BM, WINKELMAYER WC, AVORN J: A cost minimization model for the treatment of minor bleeding episodes in patients with haemophilia A and high-titre inhibitors. Haemophilia (2005) 11(3):261-269.
28. JOSHI AV, STEPHENS JM, MUNRO V, MATHEW P, BOTTEMAN MF: Pharmacoeconomic analysis of recombinant Factor VIIa versus APCC in the treatment of minor-to-moderate bleeds in hemophilia patients with inhibitors. Curr. Med. Res. Opin. (2006) 22(1):23-31.
29. SEREMETIS S, JOSHI AV, ASMUSSEN M: Cost minimization model for treatment of minor bleeding episodes in inhibitor patients - methodological issues. Haemophilia (2006) 12(1):108-109.
30. TEITEL JM: Recombinant Factor VIIa versus aPCCs in haemophiliacs with inhibitor: treatment and cost considerations. Haemophilia (1999) 5(Suppl. 3):43-49.
31. BOHN RL, ALEDORT LM, PUTNAM KG, EWENSTEIN BM, MOGUN H, AVORN J: The economic impact of Factor VIII inhibitors in patients with haemophilia. Haemophilia (2004) 10(1):63-68.
32. ALEDORT LM: Meeting report. Economic aspects of haemophdia care. Haemophilia (1999) 5(6):216-219.
33. KENET G, LUBETSKY A, LUBOSHITZ J, MARTINOWITZ U: A new approach to treatment of bleeding episodes in young hemophilia patients: a single bolus megadose of recombinant activated Factor VII (NovoSeven). J. Thromb. Haemost. (2003) 1(3):450-455.
34. KAVAKLI K, MAKRIS M, ZULFIKAR B et al.: Home treatment of haemarthroses using a single dose regimen of recombinant activated FVII in patients with haemophilia and inhibitors. A multi-centre, randomized, double-blind, cross-over trial. Thromb. Haemost. (2006) 95(4):600-605.
35. RODRIGUEZ-MERCHAN EC, ROCINO A, EWENSTEIN B et al.: Consensus perspectives on surgery in haemophilia patients with inhibitors: summary statement. Haemophilia (2004) 10(Suppl. 2):50-52.
36. HILGARTNER MW, MAKIPERNAA A, DIMICHELE DM: Long-term FEIBA prophylaxis does not prevent progression of existing joint disease. Haemophilia (2003) 9(3):261-268.